Print this page    •   Back to Web version of article

Mike Barr, TAGline Editor

Mike Barr has served as the editor of TAG's monthly newsletter since its inception. He is also Science Editor for POZ magazine. He is a founding board member of the New York-based not-for-profit group Aid for AIDS, which provides medical education and treatment to people with HIV in Latin America and the Caribbean.

Mr. Barr has worked on behalf of people with HIV since 1987, first as a member of ACT UP (AIDS Coalition to Unleash Power)/NY, as a writer of HIV treatment and research issues for NYQ and Outweek magazines, and as an employee of the American Foundation for AIDS Research (amfAR) in 1990.

From 1994 to 1996 he served as a community representative to the NIH's AIDS Clinical Trials Group (ACTG) and as a member of its Primary Infection Committee. His areas of special interest include immune based therapies, vaccines, international treatment access issues and the commercial underpinnings of the HIV research effort. From 1992-93 he participated in a clinical trial of a therapeutic AIDS vaccine. His experience with an induction/maintenance approach to antiretroviral therapy was published in the British medical journal The Lancet, [352 (9134): 1149; 3 October 1998].

Mr. Barr was born and raised in Mansfield, OH. He was graduated from the Ohio State University in 1984 where he studied finance and music; and more recently from the London School of Economics and Political Science where he studied international political economy.

This article was provided by Treatment Action Group. It is a part of the publication TAGline. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.